• 1
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556562.
  • 2
    Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. HEPATOLOGY 2002; 36(Suppl 1): S1S2.
  • 3
    Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1996; 8: 324328.
  • 4
    Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European concerted action on viral hepatitis (EUROHEP). J Hepatol 1997; 27: 201205.
  • 5
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 6
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 7
    Pavio N, Lai MM. The hepatitis C virus persistence: how to evade the immune system? J Biosci 2003; 28: 287304.
  • 8
    Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 2001; 98: 92379242.
  • 9
    Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al. Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 45314537.
  • 10
    Schmalbach T, Efler S, Morris M, Al-Adhami M, Laframboise C, Davis H, et al. CPG 10101 (ACTILON™) oligodeoxynucleotide TLR9 agonist: pharmacokinetics and pharmacodynamics in normal volunteers. In: The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Abstracts. Washington, DC: American Society for Microbiology; 2004: 463464.
  • 11
    McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, et al. Immunophenotyping profile of CPG 10101 (ACTILON™), a new TLR9 agonist antiviral for hepatitis C. HEPATOLOGY 2005; 42(Suppl 1): 539A.
  • 12
    Vollmer J, Weeratna RD, Payette PJ, Jurk M, Schetter C, Laucht M, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004; 34: 251262.
  • 13
    Efler SM, Zhang L, Noll BO, Uhlmann E, Davis HL. Quantification of oligodeoxynucleotides in human plasma with a novel hybridization assay offers greatly enhanced sensitivity over capillary gel electrophoresis. Oligonucleotides 2005; 15: 119131.
  • 14
    Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998; 28: 960964.
  • 15
    Giannini C, Thiers V, Nousbaum JB, Stuyver L, Maertens G, Brechot C. Comparative analysis of two assays for genotyping hepatitis C virus based on genotype-specific primers or probes. J Hepatol 1995; 23: 246253.
  • 16
    Guiducci C, Ott G, Chan JH, Damon E, Calacsan C, Matray T, et al. Properties regulating the nature of the plasmacytoid dendritic cell response to toll-like receptor 9 activation. J Exp Med 2006; 203: 19992008.
  • 17
    Krieg AM, Efler, SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic Th-1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CpG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004; 27: 460471.
  • 18
    Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005; 105: 489495.
  • 19
    Vollmer J, Jurk M, Samulowitz U, Lipford G, Forsbach A, Wullner M, et al. CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. J Endotoxin Res 2004; 10: 431438.
  • 20
    Vollmer J, Schetter C, Davis HL, Efler SM, Ahluwalia NK, McAuley SE, et al. Identification of a new class of CpG oligonucleotides capable of inducing both B cell proliferation and high IFN-alpha secretion from PBMC of HCV chronic carriers. Antivir Ther 2002; 7: L115.
  • 21
    Bacon BR, McHutchison JG, Gordon SC, Afdhal NH, Jacobson IM, Shiffman M, et al. Safety, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of CPG 10101 (ACTILON™), a novel TLR9 agonist: comparison in normal volunteers and HCV infected individuals. Gastroenterology 2005; 128: A696.
  • 22
    Glue P, Fang JWS, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-a2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68: 556567.
  • 23
    Formann E, Jessner W, Bennett L, Ferenci P. Twice-weekly administration of peginterferon-α-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hepatitus 2003; 10: 271276.
  • 24
    Silva M, Poo J, Wagner F, Jackson M, Cutler D, Grace M, et al. A randomized trial to compare the pharmacokinetic, pharmacodynamic, and anti-viral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatology 2006; 45: 204213.
  • 25
    Herrmann E, Lee J-H, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. HEPATOLOGY 2003; 37: 13511358.
  • 26
    Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5: 471484.
  • 27
    McHutchison JG, Bartenschlager R, Patel K, Pawlotsky JM. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 2006; 44: 411421.